{
  "paper_id": "c40321fcc587dbd862f1b7587412f81675ac5cff",
  "metadata": {
    "title": "Regulation and Testing of Vaccines",
    "coda_data_split": "train",
    "coda_paper_id": 3887,
    "coda_has_expert_labels": false,
    "subset": "custom_license"
  },
  "abstract": [
    {
      "original_text": "publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.",
      "sentences": [
        [
          {
            "segment_text": "publicly funded repositories , such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active .",
            "crowd_label": "background"
          }
        ]
      ]
    },
    {
      "original_text": "Since its inception, the FD\u0026C Act has been amended by Congress several times including the FDA Modernization Act (FDAMA) of 1997, the FDA Amendments Act (FDAAA) of 2007, and more recently, the FDA Safety and Innovation Act (FDASIA) of 2012.",
      "sentences": [
        [
          {
            "segment_text": "Since its inception , the FD\u0026C Act has been amended by Congress several times including the FDA Modernization Act ( FDAMA ) of 1997 ,",
            "crowd_label": "background"
          },
          {
            "segment_text": "the FDA Amendments Act ( FDAAA ) of 2007 ,",
            "crowd_label": "background"
          },
          {
            "segment_text": "and more recently , the FDA Safety and Innovation Act ( FDASIA ) of 2012 .",
            "crowd_label": "background"
          }
        ]
      ]
    },
    {
      "original_text": "Among other things, the FDAMA of 1997 included measures to modernize the regulation of biologics by synchronizing their review process with that of drugs and eliminating the requirement for an establishment license for biologics. Expedited approval mechanisms for life-threatening conditions also were authorized under FDAMA. 5",
      "sentences": [
        [
          {
            "segment_text": "Among other things , the FDAMA of 1997 included measures to modernize the regulation of biologics by synchronizing their review process with that of drugs and eliminating the requirement for an establishment license for biologics .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Expedited approval mechanisms for life-threatening conditions also were authorized under FDAMA .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "5",
            "crowd_label": "other"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "3",
    "sentence_num": "6",
    "segment_num": "8",
    "token_num": "151"
  }
}